CA2506082C — Novel medicaments for the treatment of chronic obstructive pulmonary disease
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2011-06-21 · 15y expired
What this patent protects
The invention relates to the use of compounds of general formula (1): (see formula I) including those wherein n denotes 1; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; and R3 denotes hydrogen, …
USPTO Abstract
The invention relates to the use of compounds of general formula (1): (see formula I) including those wherein n denotes 1; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; and R3 denotes hydrogen, halogen, C1-C4-alkyl, -O-C1-C4-alkyl, -O-CH2-COOH, -O-CH2-COOmethyl or -O-CH2-COOethyl for the production of a medicament for the treatment of COPD (Chronic Obstructive Pulmonary Disease) and novel compounds of general formula (I) as such.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.